The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

Stephen D. Wiviott, Eugene Braunwald, Carolyn H. McCabe et al. · New England Journal of Medicine · 2007 · 6.7K citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +1

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention

Stephen D. Wiviott, Dietmar Trenk, Andrew L. Frelinger et al. · Circulation · 2007 · 877 citations

Medicine, Pharmacology, Pharmacotherapy +17

Identification and Biological Activity of the Active Metabolite of Clopidogrel

Pierre Savi, Jean‐Marie Pereillo, Marie-Françoise Uzabiaga et al. · Thrombosis and Haemostasis · 2000 · 748 citations

Medicine, Medicinal Chemistry, Pharmacology +17

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

John T. Brandt, Christopher D. Payne, Stephen D. Wiviott et al. · American Heart Journal · 2006 · 570 citations

Medicine, Pharmacokinetics, Pharmacology +17

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Tomas Jernberg, Christopher D. Payne, Kenneth J. Winters et al. · European Heart Journal · 2006 · 536 citations · Full text

Medicine, Cardiology, Pharmacology +17